Cyclin D1, cancer progression, and opportunities in cancer treatment.
about
Transcriptomic Profiling of Posterior Polymorphous Corneal Dystrophy.Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells.Fbxo4-mediated degradation of Fxr1 suppresses tumorigenesis in head and neck squamous cell carcinoma.Overexpression and biological function of MEF2D in human pancreatic cancer.Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).Regulator of G protein signaling 4 inhibits human melanoma cells proliferation and invasion through the PI3K/AKT signaling pathway.Inhibitory effect of pyrvinium pamoate on uveal melanoma cells involves blocking of Wnt/β-catenin pathway.Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway.SALL2 represses cyclins D1 and E1 expression, and restrains G1/S cell cycle transition and cancer-related phenotypes.Bradykinin potentially stimulates cell proliferation in rabbit corneal endothelial cells through the ZO‑1/ZONAB pathway.Unraveling the Inconsistencies of Cardiac Differentiation Efficiency Induced by the GSK3β Inhibitor CHIR99021 in Human Pluripotent Stem Cells.Gomisin G Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing AKT Phosphorylation and Decreasing Cyclin D1.Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas.Oncogenic c-terminal cyclin D1 (CCND1) mutations are enriched in endometrioid endometrial adenocarcinomasCyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXAFueling the Cycle: CDKs in Carbon and Energy Metabolism
P2860
Q33847709-196FFB1D-AE1A-402D-BA1D-1CB83811B3F7Q37631444-C9168CE0-6C38-4B7A-B306-77717F38923BQ46089793-58BB4714-E189-4FED-852A-968F3E772530Q47110609-A7D1B8B2-F427-46ED-A584-3B7FE6F1C7B5Q47269802-B64B3ECB-11BF-4F73-B962-416B17674712Q47435317-00B90C0A-2E19-4214-8EAF-7100351C0FBAQ47692716-3604CED0-1853-4761-ABF2-948E23B94309Q50067502-FB986D28-A7E2-4292-BCEF-B1626DD5314FQ52566582-EC4C3A22-EA80-4D11-97FD-4E88C37D9516Q52641279-26C565AF-327F-4950-A8E9-71C2C8E96C63Q52715883-A30FFD8D-9309-4BF2-8BEF-F4CC8B5CC2DDQ52723797-6EADEAE2-A3A8-4487-8C86-5086FCCEA4D7Q54123926-560E1803-0F0E-4D49-823A-CBC6DA41FD95Q57177365-CB358C98-472F-4E86-AEE4-44CE606603E4Q58765200-5FE80D1F-370B-4B01-866F-DC7A117EBA5EQ58769406-4F6B6094-C5ED-453A-8CFE-FFA8658DDE6E
P2860
Cyclin D1, cancer progression, and opportunities in cancer treatment.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Cyclin D1, cancer progression, and opportunities in cancer treatment.
@en
type
label
Cyclin D1, cancer progression, and opportunities in cancer treatment.
@en
prefLabel
Cyclin D1, cancer progression, and opportunities in cancer treatment.
@en
P2860
P1476
Cyclin D1, cancer progression, and opportunities in cancer treatment
@en
P2093
J Alan Diehl
P2860
P2888
P304
P356
10.1007/S00109-016-1475-3
P50
P577
2016-10-02T00:00:00Z
P6179
1040239054